{
  "doc_id": "R4- Bronchospasm_Asthma_COPD_APR22",
  "file_path": "C:\\Users\\SAHARA\\OneDrive\\Desktop\\uni\\gemma\\risk_score\\rag_store\\sop_pdfs\\R4- Bronchospasm_Asthma_COPD_APR22.pdf",
  "pages": [
    {
      "page_num": 1,
      "text": "April 2022 County of Marin EMS R 4\nBRONCHOSPASM/ASTHMA/COPD\nIndications\n• Acute or progressive shortness of breath, chest discomfort, wheezing, cyanosis\nALS RMC\nMild to Moderate Severe\n• Pt may be unable to speak full • Altered mental status\nsentences • Minimal air movement\n• Minimal accessory muscle use • Inability to speak\n• Significant desaturation <90%\n• Cyanosis\n• Albuterol 5mg in 6ml NS HHN\n• MR if necessary\n• Atrovent 500mcg (2.5ml) HHN • Consider CPAP\n• Albuterol 5mg in 6ml NS HHN\n• MR if necessary\n• Atrovent 500mcg (2.5ml) HHN\n• If Albuterol and Atrovent not\neffective:\n• Epinephrine 0.3mg IM\n(1mg/ml concentration)\n• MR once in 5 min\nSPECIAL CONSIDERATIONS\n• Do not repeat Albuterol/Atrovent if significant tachycardia or chest pain\n• Epinephrine side effects may include anxiety, tremor, tachycardia, HTN and headache\n• Consider use of patient actuated nebulizer with prolonged scene times and/or transport times\nover 10 minutes.\n• Suspected carbon monoxide in cases of exposure to fire or smoke in confined areas; pulse\noximetry in these settings is not accurate measure of respiratory status",
      "image_path": null
    }
  ]
}